Manic or mixed episodes associated with bipolar I disorder

Active Ingredient: Iloperidone

Indication for Iloperidone

Population group: only adults (18 years old or older)
Therapeutic intent: Curative procedure

Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.

For this indication, competent medicine agencies globally authorize below treatments:

1 mg twice daily on Day 1, 3 mg twice daily on Day 2, 6 mg twice daily on Day 3, 9 mg twice daily on Day 4, 12 mg twice daily on Day 5 and thereafter

For:

Dosage regimens

Oral, 1 milligrams iloperidone, 2 times daily, over the duration of 1 day. Afterwards, oral, 3 milligrams iloperidone, 2 times daily, over the duration of 1 day. Afterwards, oral, 6 milligrams iloperidone, 2 times daily, over the duration of 1 day. Afterwards, oral, 9 milligrams iloperidone, 2 times daily, over the duration of 1 day. Afterwards, oral, 12 milligrams iloperidone, 2 times daily.

Detailed description

Titrate iloperidone to avoid orthostatic hypotension. The table below includes dosage recommendations for iloperidone for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.

Dosage recommendations for iloperidone in adults for the acute treatment of manic or mixed episodes associated with bipolar I disorder:

Indication and
population
Titration schedule Recommended
dosage
Day 1Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
Bipolar I disorder
manic or mixed
episodes
1 mg
twice
daily
3 mg
twice
daily
6 mg
twice
daily
9 mg
twice
daily
12 mg
twice
daily
Titration complete 12 mg
twice daily

Reinitiation of treatment in patients previously discontinued

Although there are no data to specifically address reinitiation of treatment, it is recommended that the initiation titration schedule be followed whenever patients have had an interval off iloperidone of more than 3 days.

Dosage considerations

Administer iloperidone orally with or without food.

Active ingredient

Iloperidone

The mechanism of action of iloperidone in schizophrenia and bipolar I disorder is unknown. However, the efficacy of iloperidone could be mediated through a combination of dopamine type 2 (D2) and serotonin type 2 (5-HT2) antagonism. Iloperidone forms an active metabolite, P88, that has an in vitro receptor binding profile similar to the parent drug.

Read more about Iloperidone

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.